Showing results (11-20 of 52) with videos related to

Sort By:
Pageof 6
Antimicrobial Agents and Chemotherapy|December 4, 2013
Raltegravir has a low propensity to cause clinical drug interactions through inhibition of major drug transporters: an in vitro evaluationMatthew L Rizk, Robert Houle, Grace Hoyee Chan, et al.
Analytical Chemistry|October 4, 2012
Ultrasensitive liquid chromatography-tandem mass spectrometric methodologies for quantification of five HIV-1 integrase inhibitors in plasma for a microdose clinical trialLi Sun, Hankun Li, Kenneth Willson, et al.
Antimicrobial Agents and Chemotherapy|April 10, 2019
Ceftolozane-Tazobactam Population Pharmacokinetics and Dose Selection for Further Clinical Evaluation in Pediatric Patients with Complicated Urinary Tract or Complicated Intra-abdominal InfectionsKajal B Larson, Yogesh T Patel, Susan Willavize, et al.
Antimicrobial Agents and Chemotherapy|January 26, 2026
Imipenem/cilastatin/relebactam dosing regimen justification using exposure-efficacy analyses in participants with hospital-acquired bacterial pneumonia or ventilator-associated bacterial pneumonia in the RESTORE-IMI 2 phase 3 studyMunjal Patel, Garrett Nieddu, C Andrew DeRyke, et al.
CPT: Pharmacometrics & Systems Pharmacology|September 12, 2019
Population Pharmacokinetic Analysis for Imipenem-Relebactam in Healthy Volunteers and Patients With Bacterial InfectionsPratik Bhagunde, Parul Patel, Mallika Lala, et al.
Clinical Pharmacology and Therapeutics|July 21, 2020
Pharmacokinetics and Pharmacological Properties of Chloroquine and Hydroxychloroquine in the Context of COVID-19 InfectionMelanie R Nicol, Abhay Joshi, Matthew L Rizk, et al.
CPT: Pharmacometrics & Systems Pharmacology|May 2, 2021
Understanding effect site pharmacology of uprifosbuvir, a hepatitis C virus nucleoside inhibitor: Case study of a multidisciplinary modeling approach in drug developmentPaul van den Berg, Wei Gao, Maurice J Ahsman, et al.
American Journal of Perinatology|January 8, 2020
Ceftolozane/Tazobactam in Neonates and Young Infants: The Challenges of Collecting Pharmacokinetics and Safety Data in This Vulnerable Patient PopulationJocelyn Y Ang, Antonio Arrieta, John S Bradley, et al.
Clinical Pharmacology and Therapeutics|April 5, 2023
Factors Influencing COVID-19 Risk: Insights From Molnupiravir Exposure-Response Modeling of Clinical OutcomesAkshita Chawla, Ruthie Birger, Hong Wan, et al.
Antiviral Therapy|March 11, 2014
A pharmacokinetic comparison of adult and paediatric formulations of raltegravir in healthy adultsElizabeth G Rhee, Matthew L Rizk, Diana M Brainard, et al.
Pageof 6